TY - JOUR
T1 - Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population
T2 - A Multinational Case Series
AU - Testi, Ilaria
AU - Brandão-de-Resende, Camilo
AU - De-La-Torre, Alejandra
AU - Concha-Del-Rio, Luz Elena
AU - Cheja-Kalb, Rashel
AU - Mahendradas, Padmamalini
AU - Habot-Wilner, Zohar
AU - Yalçındağ, Nilüfer
AU - Markelj, Špela
AU - Iriqat, Salam
AU - Portero, Alejandro
AU - Petrushkin, Harry
AU - Pavesio, Carlos
AU - Solebo, Ameenat Lola
N1 - Publisher Copyright:
© 2023 Taylor & Francis Group, LLC.
PY - 2023/6/14
Y1 - 2023/6/14
N2 - Background: Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population. Methods: Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination. Results: Twenty individuals were included. The most common event was anterior uveitis (n = 8, 40.0%), followed by intermediate uveitis (7 patients, 35%), panuveitis (4 patients, 20%), and posterior uveitis (1 patient, 5%). The event was noticed in the first week after vaccination in 11 patients (55.0%). Twelve patients (60.0%) had a previous history of intraocular inflammatory event. Patients were managed with topical corticosteroids (n = 19, 95.0%), oral corticosteroids (n = 10, 50.0%), or increased dose of immunosuppressive treatment (n = 6, 30.0%). Thirteen patients (65.0%) had a complete resolution of the ocular event without complications. All patients had a final visual acuity unaffected or less than three lines of loss. Conclusion: Ocular inflammatory events may happen in the paediatric population following COVID-19 vaccination. Most events were successfully treated, and all showed a good visual outcome.
AB - Background: Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population. Methods: Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination. Results: Twenty individuals were included. The most common event was anterior uveitis (n = 8, 40.0%), followed by intermediate uveitis (7 patients, 35%), panuveitis (4 patients, 20%), and posterior uveitis (1 patient, 5%). The event was noticed in the first week after vaccination in 11 patients (55.0%). Twelve patients (60.0%) had a previous history of intraocular inflammatory event. Patients were managed with topical corticosteroids (n = 19, 95.0%), oral corticosteroids (n = 10, 50.0%), or increased dose of immunosuppressive treatment (n = 6, 30.0%). Thirteen patients (65.0%) had a complete resolution of the ocular event without complications. All patients had a final visual acuity unaffected or less than three lines of loss. Conclusion: Ocular inflammatory events may happen in the paediatric population following COVID-19 vaccination. Most events were successfully treated, and all showed a good visual outcome.
UR - http://www.scopus.com/inward/record.url?scp=85161944022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161944022&partnerID=8YFLogxK
U2 - 10.1080/09273948.2023.2220782
DO - 10.1080/09273948.2023.2220782
M3 - Article
C2 - 37315304
AN - SCOPUS:85161944022
SN - 0927-3948
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -
